An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs MIV 711 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Medivir AB
- 25 Jul 2017 According to a Medivir AB media release, data from this study will be available in the first quarter of 2018.
- 09 Jun 2017 The independent Data Monitoring Committee (DMC) has recommended continuation of the extension study based on a review of the accumulated safety data according to a Medivir AB media release.
- 09 Jun 2017 Status changed from recruiting to active, no longer recruiting according to a Medivir AB media release.